PLGA nanoparticles containing a-fetoprotein siRNA induce apoptosis and enhance the cytotoxic effects of doxorubicin in human liver cancer cell line

被引：14

作者：

Pho-iam, Theeraphong ^{[1
]}

Punnakitikashem, Primana ^{[1
,2
]}

Somboonyosdech, Chayapol ^{[1
]}

Sripinitchai, Sirinapa ^{[1
]}

Masaratana, Patarabutr ^{[1
,2
]}

Sirivatanauksorn, Vorapan ^{[1
,2
]}

Sirivatanauksorn, Yongyut ^{[2
,3
]}

Wongwan, Chamaiphorn ^{[1
]}

Nguyen, Kytai T. ^{[4
]}

Srisawat, Chatchawan ^{[1
,2
]}

机构：

[1] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Biochem, Bangkok 10700, Thailand

[2] Res Network NANOTEC MU Theranost Nanomed, Bangkok, Thailand

[3] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Surg, Bangkok 10700, Thailand

[4] Univ Texas Arlington, Dept Bioengn, Arlington, TX 76019 USA

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2021年 / 553卷

关键词：

a-fetoprotein; Doxorubicin; poly(lactic-co-glycolic) acid; PLGA; Nanoparticle; siRNA; Hepatocellular carcinoma; HEPATOCELLULAR-CARCINOMA; ALPHA-FETOPROTEIN; TARGETED THERAPY; PROLIFERATION; CHEMOTHERAPY; EXPRESSION; CISPLATIN; PROFILE;

D O I：

10.1016/j.bbrc.2021.03.086

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Hepatocellular carcinoma (HCC) is one of the most common cancers and is a leading cause of death. Delivery of therapeutic molecules, e.g., siRNA, to HCC cells could potentially be an alternative treatment for HCC. In this study, the siRNA targeting a-fetoprotein (AFP) mRNA was found to specifically induce apoptosis and significant cell death in HepG2 cells. It also enhanced the cytotoxic effects of doxorubicin by about two-fold, making it the candidate therapeutic molecule for HCC treatment. To deliver the siRNAs into HCC cells, the AFP siRNAs were loaded into the nanoparticles based on poly (lactic-co-gly-colic) acid (PLGA). These nanoparticles induced apoptosis in HepG2 cells and synergistically increased the cytotoxicity of doxorubicin. In summary, the delivery of the AFP siRNA-loaded PLGA nanoparticles in combination with doxorubicin could be a very promising approach for the treatment of HCC. ? 2021 Elsevier Inc. All rights reserved.

引用

页码：191 / 197

页数：7

共 29 条

[1] Abelev G I, 1971, Adv Cancer Res, V14, P295, DOI 10.1016/S0065-230X(08)60523-0
[2] Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14
Cho, Yuri
Lee, Yun Bin
Lee, Jeong-Hoon
Lee, Dong Hyeon
Cho, Eun Ju
Yu, Su Jong
Kim, Yoon Jun
Kim, Jong In
Im, Jong Hun
Lee, Jung Hwan
Oh, Eun Ju
Yoon, Jung-Hwan
[J]. PLOS ONE, 2016, 11 (08):
[3] Chung EJ, 2002, MOL CELLS, V14, P382
[4] Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review
Daher, Saleh
Massarwa, Muhammad
Benson, Ariel A.
Khoury, Tawfik
[J]. JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2018, 6 (01) : 69 - 78
[5] PLGA-based nanoparticles: An overview of biomedical applications
Danhier, Fabienne
Ansorena, Eduardo
Silva, Joana M.
Coco, Regis
Le Breton, Aude
Preat, Veronique
[J]. JOURNAL OF CONTROLLED RELEASE, 2012, 161 (02) : 505 - 522
[6] RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase -: art. no. e46
Donzé, O
Picard, D
[J]. NUCLEIC ACIDS RESEARCH, 2002, 30 (10) : e46
[7] The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
Fang, Jun
Nakamura, Hideaki
Maeda, Hiroshi
[J]. ADVANCED DRUG DELIVERY REVIEWS, 2011, 63 (03) : 136 - 151
[8] Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
Ferlay, J.
Colombet, M.
Soerjomataram, I.
Mathers, C.
Parkin, D. M.
Pineros, M.
Znaor, A.
Bray, F.
[J]. INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (08) : 1941 - 1953
[9] Görög D, 2005, WORLD J GASTROENTERO, V11, P5015
[10] Chemotherapy for hepatocellular carcinoma: current status and future perspectives
Ikeda, Masafumi
Morizane, Chigusa
Ueno, Makoto
Okusaka, Takuji
Ishii, Hiroshi
Furuse, Junji
[J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (02) : 103 - 114

← 1 2 3 →